Patents Assigned to Vivera Pharmaceuticals Inc.
  • Publication number: 20230114360
    Abstract: Sublingual delivery vehicles (SDVs) including tablets and gel strips may mitigate or eliminate side effects associated with active ingredients included in the SDVs. An exemplary SDV may include: an ingredient mixture including a flavoring agent and a lubricant; and a specified dose of zicronapine, wherein the SDV dissolves within thirty seconds of sublingual administration. A method of manufacturing an SDV may include mixing a set of ingredients, wherein the set of ingredients includes: a flavoring agent, a lubricant, and a specified dose of zicronapine; and forming the SDV from the mixed set of ingredients. A method for treating mental disorders may include administering, once a day, an ingredient mixture including: a flavoring agent; a lubricant; and a specified dose of zicronapine, wherein the ingredient mixture is administered via a sublingual delivery vehicle (SDV).
    Type: Application
    Filed: December 13, 2022
    Publication date: April 13, 2023
    Applicants: Vivera Pharmaceuticals Inc., Vivera Pharmaceuticals Inc.
    Inventors: Paul Edalat, Gerald A. Maguire, MD, Stephen J. McColgan, MD
  • Publication number: 20230104820
    Abstract: A sanitization device and telemedicine station (SDTS) may automatically detect and disinfect users as the users pass through the device. Sanitizing solution may be distributed throughout a disinfecting area within the SDTS such that people, pets, items, and/or other objects are disinfected. The SDTS may collect biometric data such as body temperature. Collected data may be analyzed to identify conditions and/or generate recommendations by matching collected data to various condition profiles. The SDTS may allow telemedicine sessions, where a user may communicate with a practitioner or virtual practitioner.
    Type: Application
    Filed: August 5, 2022
    Publication date: April 6, 2023
    Applicant: Vivera Pharmaceuticals Inc.
    Inventors: Mehdi Hatamian, Paul Edalat
  • Patent number: 11594149
    Abstract: Speech fluency evaluation and feedback tools are described. A computing device such as a smartphone may be used to collect speech (and/or other data). The collected data may be analyzed to detect various speech events (e.g., stuttering) and feedback may be generated and provided based on the detected speech events. The collected data may be used to generate a fluency score or other performance metric associated with speech. Collected data may be provided to a practitioner such as a speech therapist or physician for improved analysis and/or treatment.
    Type: Grant
    Filed: April 7, 2022
    Date of Patent: February 28, 2023
    Assignee: Vivera Pharmaceuticals Inc.
    Inventors: Paul Edalat, Gerald A. Maguire, Mehdi Hatamian
  • Patent number: 11450420
    Abstract: A smart dosing device includes: a supply pathway having a compartment that is able to house multiple discrete doses of a substance; at least one sensor that captures identifying information related to the substance; a wireless communication module; and at least one security feature that restricts use of the smart dosing device. A method of providing a measured dose using a smart dosing device includes: retrieving a discrete dose from a storage cavity of the smart dosing device; and providing the discrete dose via an outlet port of the device. A smart dosing system includes: a smart dosing device having a unique identifier, the smart dosing device including a cartridge housing multiple discrete doses of a substance, the cartridge having a unique cartridge identifier; and a server including a central database that stores usage information related to the smart dosing device including the unique identifier and the unique cartridge identifier.
    Type: Grant
    Filed: August 9, 2021
    Date of Patent: September 20, 2022
    Assignee: Vivera Pharmaceuticals Inc.
    Inventors: Mehdi Hatamian, Paul Edalat
  • Patent number: 11406728
    Abstract: A sanitization device and telemedicine station (SDTS) may automatically detect and disinfect users as the users pass through the device. Sanitizing solution may be distributed throughout a disinfecting area within the SDTS such that people, pets, items, and/or other objects are disinfected. The SDTS may collect biometric data such as body temperature. Collected data may be analyzed to identify conditions and/or generate recommendations by matching collected data to various condition profiles. The SDTS may allow telemedicine sessions, where a user may communicate with a practitioner or virtual practitioner.
    Type: Grant
    Filed: October 9, 2020
    Date of Patent: August 9, 2022
    Assignee: Vivera Pharmaceuticals Inc.
    Inventors: Mehdi Hatamian, Paul Edalat
  • Publication number: 20220168226
    Abstract: Sublingual delivery vehicles (SDVs) including tablets and gel strips may mitigate or eliminate side effects associated with active ingredients included in the SDVs. An exemplary SDV may include: an ingredient mixture including a flavoring agent and a lubricant; and a specified dose of metformin, wherein the SDV dissolves within thirty seconds of sublingual administration. A method of manufacturing an SDV may include mixing a set of ingredients, wherein the set of ingredients includes: a flavoring agent, a lubricant, and a specified dose of metformin; and forming the SDV from the mixed set of ingredients. A method for treating mental disorders may include administering, once a day, an ingredient mixture including: a flavoring agent; a lubricant; and a specified dose of metformin, wherein the ingredient mixture is administered via a sublingual delivery vehicle (SDV).
    Type: Application
    Filed: February 16, 2022
    Publication date: June 2, 2022
  • Publication number: 20220117901
    Abstract: Sublingual delivery vehicles (SDVs) including tablets and gel strips may mitigate or eliminate side effects associated with active ingredients included in the SDVs. An exemplary SDV may include: an ingredient mixture including a flavoring agent and a lubricant; and a specified dose of brexpiprazole, wherein the SDV dissolves within thirty seconds of sublingual administration. A method of manufacturing an SDV may include mixing a set of ingredients, wherein the set of ingredients includes: a flavoring agent, a lubricant, and a specified dose of brexpiprazole; and forming the SDV from the mixed set of ingredients. A method for treating mental disorders may include administering, once a day, an ingredient mixture including: a flavoring agent; a lubricant; and a specified dose of brexpiprazole, wherein the ingredient mixture is administered via a sublingual delivery vehicle (SDV).
    Type: Application
    Filed: December 31, 2021
    Publication date: April 21, 2022
  • Publication number: 20220117900
    Abstract: Sublingual delivery vehicles (SDVs) including tablets and gel strips may mitigate or eliminate side effects associated with active ingredients included in the SDVs. An exemplary SDV may include: an ingredient mixture including a flavoring agent and a lubricant; and a specified dose of vortioxetine, wherein the SDV dissolves within thirty seconds of sublingual administration. A method of manufacturing an SDV may include mixing a set of ingredients, wherein the set of ingredients includes: a flavoring agent, a lubricant, and a specified dose of vortioxetine; and forming the SDV from the mixed set of ingredients. A method for treating mental disorders may include administering, once a day, an ingredient mixture including: a flavoring agent; a lubricant; and a specified dose of vortioxetine, wherein the ingredient mixture is administered via a sublingual delivery vehicle (SDV).
    Type: Application
    Filed: December 31, 2021
    Publication date: April 21, 2022
  • Publication number: 20220111091
    Abstract: A sanitization device and telemedicine station (SDTS) may automatically detect and disinfect users as the users pass through the device. Sanitizing solution may be distributed throughout a disinfecting area within the SDTS such that people, pets, items, and/or other objects are disinfected. The SDTS may collect biometric data such as body temperature. Collected data may be analyzed to identify conditions and/or generate recommendations by matching collected data to various condition profiles. The SDTS may allow telemedicine sessions, where a user may communicate with a practitioner or virtual practitioner.
    Type: Application
    Filed: October 9, 2020
    Publication date: April 14, 2022
  • Publication number: 20220096387
    Abstract: Sublingual delivery vehicles (SDVs) including tablets and gel strips may mitigate or eliminate side effects associated with active ingredients included in the SDVs. An exemplary SDV may include: an ingredient mixture including a flavoring agent and a lubricant; and a specified dose of lurasidone, wherein the SDV dissolves within thirty seconds of sublingual administration. A method of manufacturing an SDV may include mixing a set of ingredients, wherein the set of ingredients includes: a flavoring agent, a lubricant, and a specified dose of lurasidone; and forming the SDV from the mixed set of ingredients. A method for treating mental disorders may include administering, once a day, an ingredient mixture including: a flavoring agent; a lubricant; and a specified dose of lurasidone, wherein the ingredient mixture is administered via a sublingual delivery vehicle (SDV).
    Type: Application
    Filed: December 8, 2021
    Publication date: March 31, 2022
  • Publication number: 20220062189
    Abstract: Sublingual delivery vehicles (SDVs) including tablets and gel strips may mitigate or eliminate side effects associated with active ingredients included in the SDVs. An exemplary SDV may include: an ingredient mixture including a flavoring agent and a lubricant; and a specified dose of sildenafil citrate, wherein the SDV dissolves within thirty seconds of sublingual administration. A method of manufacturing an SDV may include mixing a set of ingredients, wherein the set of ingredients includes: a flavoring agent, a lubricant, and a specified dose of sildenafil citrate; and forming the SDV from the mixed set of ingredients. A method for treating mental disorders may include administering, once a day, an ingredient mixture including: a flavoring agent; a lubricant; and a specified dose of sildenafil citrate, wherein the ingredient mixture is administered via a sublingual delivery vehicle (SDV).
    Type: Application
    Filed: November 10, 2021
    Publication date: March 3, 2022
  • Publication number: 20220023223
    Abstract: Sublingual delivery vehicles (SDVs) including tablets and gel strips may mitigate or eliminate side effects associated with active ingredients included in the SDVs. An exemplary SDV may include: an ingredient mixture including a flavoring agent and a lubricant; and a specified dose of blonanserin, wherein the SDV dissolves within thirty seconds of sublingual administration. A method of manufacturing an SDV may include mixing a set of ingredients, wherein the set of ingredients includes: a flavoring agent, a lubricant, and a specified dose of blonanserin; and forming the SDV from the mixed set of ingredients. A method for treating mental disorders may include administering, once a day, an ingredient mixture including: a flavoring agent; a lubricant; and a specified dose of blonanserin, wherein the ingredient mixture is administered via a sublingual delivery vehicle (SDV).
    Type: Application
    Filed: October 6, 2021
    Publication date: January 27, 2022
  • Publication number: 20210401758
    Abstract: Sublingual delivery vehicles (SDVs) including tablets and gel strips may mitigate or eliminate side effects associated with active ingredients included in the SDVs. An exemplary SDV may include: an ingredient mixture including a flavoring agent and a lubricant; and a specified dose of trazodone, wherein the SDV dissolves within thirty seconds of sublingual administration. A method of manufacturing an SDV may include mixing a set of ingredients, wherein the set of ingredients includes: a flavoring agent, a lubricant, and a specified dose of trazodone; and forming the SDV from the mixed set of ingredients. A method for treating mental disorders may include administering, once a day, an ingredient mixture including: a flavoring agent; a lubricant; and a specified dose of trazodone, wherein the ingredient mixture is administered via a sublingual delivery vehicle (SDV).
    Type: Application
    Filed: September 1, 2021
    Publication date: December 30, 2021
  • Publication number: 20210401757
    Abstract: Sublingual delivery vehicles (SDVs) including tablets and gel strips may mitigate or eliminate side effects associated with active ingredients included in the SDVs. An exemplary SDV may include: an ingredient mixture including a flavoring agent and a lubricant; a specified dose of olanzapine; and a specified dose of metformin, wherein the SDV dissolves within thirty seconds of sublingual administration. A method of manufacturing an SDV may include mixing a set of ingredients, wherein the set of ingredients includes: a flavoring agent, a lubricant, a specified dose of olanzapine, and a specified dose of metformin; and forming the SDV from the mixed set of ingredients. A method for treating mental disorders may include administering, twice per day, an ingredient mixture including: a flavoring agent; a lubricant; a specified dose of olanzapine; and a specified dose of metformin, wherein the ingredient mixture is administered via a sublingual delivery vehicle (SDV).
    Type: Application
    Filed: September 1, 2021
    Publication date: December 30, 2021
  • Publication number: 20210366589
    Abstract: A smart dosing device includes: a supply pathway having a compartment that is able to house a plurality of discrete doses of a particular substance; at least one sensor that captures identifying information related to the particular substance; a wireless communication module; and at least one security feature that restricts use of the smart dosing device. A method of providing a measured dose using a smart dosing device includes: retrieving a discrete dose from a storage cavity of the smart dosing device; and providing the discrete dose via an outlet port of the smart dosing device. A smart dosing system includes: a smart dosing device having a unique identifier, the smart dosing device including a cartridge housing multiple discrete doses of a substance, the cartridge having a unique cartridge identifier; and a server including a central database that stores usage information related to the smart dosing device, the usage information comprising: the unique identifier and the unique cartridge identifier.
    Type: Application
    Filed: August 9, 2021
    Publication date: November 25, 2021
  • Publication number: 20210311056
    Abstract: A self-administered tester for infection may include a sample collection element for receiving fluid samples including bodily fluids. The sample collection elements may provide at least a portion of a collected sample to one or more evaluation elements. Each evaluation element may determine whether some evaluation criteria have been satisfied. Result indicators may provide visual indicators showing whether the evaluation criteria were satisfied. The self-administered tester may test for a Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection using evaluators associated with the Immunoglobulin G (IgG) antibody and the Immunoglobulin M (IgM) antibody.
    Type: Application
    Filed: April 1, 2021
    Publication date: October 7, 2021
  • Patent number: 11090449
    Abstract: A smart inhaler device includes: a flow pathway having a cartridge receptacle that is able to house a cartridge, flow meter, pump, and vaporizer; a wireless communication module; and at least one sensor that captures identifying information related to the cartridge. A method of providing a measured dose using a smart inhaler device includes: enabling dosing; measuring a provided dose; and disabling dosing. A smart inhaler system includes: a smart inhaler device; a user device; and a server.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: August 17, 2021
  • Patent number: 11083850
    Abstract: A smart dosing device includes: a flow pathway having a cartridge receptacle that is able to house a cartridge; at least one sensor that captures identifying information related to the cartridge; a wireless communication module; and at least one security feature that restricts use of the smart dosing device. A method of providing a measured dose using a smart dosing device includes: enabling dosing; measuring a provided dose; and disabling dosing. A smart dosing system includes: a smart dosing device having a unique identifier, the smart dosing device including a cartridge housing a substance, the cartridge having a unique cartridge identifier; and a server including a central database that stores usage information related to the smart dosing device, the usage information including: the unique identifier and the unique cartridge identifier.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: August 10, 2021